Elsevier

Journal of Cardiac Failure

Volume 3, Issue 3, September 1997, Pages 173-179
Journal of Cardiac Failure

Clinical investigation
Safety and efficacy of carvedilol in severe heart failure,☆☆

https://doi.org/10.1016/S1071-9164(97)90013-0Get rights and content
Under a Creative Commons license
open archive

Abstract

Background: Many patients remain markedly symptomatic despite optimal current therapy for heart failure. Beta-blockers have often been viewed as contraindicated in this group because of their potential adverse short-term effects on cardiac function.

Methods and Results: One hundred thirty-one patients with severe congestive heart failure were enrolled into a double-blind, placebo-controlled study of the vasodilating beta-blocker carvedilol. All patients had symptomatic, advanced heart failure while on standard triple therapy, as evidenced by a mean ejection fraction of 0.22, marked reduction in distance traveled in a 6-minute corridor walk test, and severe impairment in quality of life measured by the Minnesota Living With Heart Failure Questionnaire. After a 2-week, open-label test of 6.25 mg twice daily carvedilol, 105 patients were randomized (2:1) to receive either carvedilol (up to 25 mg twice daily, n = 70) or matching placebo (n = 35) for 6 months while background therapy with digoxin, diuretics, and an angiotensin-converting enzyme inhibitor remained constant. Ten patients (8%) did not complete the open-label period because of adverse events and 11.4% in both the carvedilol and placebo groups dropped out in the double-blind phase. The study was terminated early by the Data Safety and Monitoring Board and follow-up evaluation was therefore aborted before the projected number of patients and follow-up time was achieved. Quality of life, which was the primary endpoint, improved similarly in the carvedilol and placebo groups, whereas the global assessment by the physicians and the patient exhibited a better response to carvedilol (P < .05). Hospitalization and mortality rate were too low to evaluate a difference, and exercise time and New York Heart Association classification did not change significantly in response to the drug. Left ventricular ejection fraction rose significantly (+0.09) in the carvedilol group compared with the placebo group (+0.02, P = .004).

Conclusion: The beta-blocker carvedilol can be safely employed in patients with severe heart failure. Improved left ventricular function with a trend for some improvement in symptoms combined with the experience with the drug in the larger population of less severe patients in this multicenter trial suggests that carvedilol may have a favorable long-term effect in heart failure of diverse severity.

Keywords

carvedilol
beta-blocker
heart failure
quality of life

Cited by (0)

Supported by SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, and Boehringer Mannheim Therapeutics, Mannheim, Germany.

☆☆

All editorial decisions for this article, including selection of referees, were made by a guest editor. This policy applies to all articles with authors from the University of Minnesota.

1

The Carvedilol Heart Failure Study Group Investigators are listed in the appendix.